Investigator-Initiated Studies (IIS)

Dermira is committed to constant innovation in the field of medical dermatology and recognizes the contribution of investigator-initiated studies (IIS) toward this goal. We recognize the critical role IIS can play in the overall expansion of medical knowledge and in generation of further research avenues to improve treatments for patients affected by chronic skin conditions. Dermira supports IIS efforts through providing drug product, funding or both.

Areas of Interest

  • Diagnosis and clinical assessment of hyperhidrosis
  • Impact of hyperhidrosis on patient and caregiver quality of life
  • Optimization of glycopyrronium cloth as a component of hyperhidrosis treatment
  • Exploratory studies evaluating glycopyrronium cloth for other indications, including primary focal (E.g., palmar, plantar, craniofacial) and multi-focal hyperhidrosis.


Evaluation Criteria

  • Scientific and medical merit
  • Alignment with Dermira strategic priorities and vision
  • Feasibility of study protocol
  • Reasonableness of study budget

Required IIS Concept Application Materials

  • Submission of signed, completed IIS Concept Application (find application below to download)
  • W-9 Form of your organization
  • Curriculum Vitae (CV) of proposed principal study investigator

Form Downloads

Please download the application, fill out completely and return along with the above required materials via email or mail printouts to:
Grants Coordinator
275 Middlefield Road, Suite 150
Menlo Park, CA 94025

If you are emailing, an electronic signature will be required.

Dermira IIS Concept Application (in fillable PDF and Word formats for download)


This Investigator Initiated Study (IIS) Concept Application and required materials must be submitted as the first step for consideration of an IIS grant from Dermira Inc. The Dermira Grants Committee will convene to review this IIS Concept Application. The Grants Coordinator will then communicate the committee decision to the Requestor as either 1) a formal acceptance of the concept submitted and subsequent invitation to complete and submit an IIS Full Application or 2) a formal decline of the concept submitted.

Please see our Privacy Policy regarding data submitted via application forms.

Compliance Commitment

Dermira, Inc. is committed to compliance with all applicable federal and state pharmaceutical industry laws, regulations, and industry guidelines. Submission of this concept application does not constitute or represent a funding commitment by Dermira, Inc. Such a funding decision is subject to Dermira Inc.’s internal approval of an IIS Full Application, if so invited of the Requestor. This IIS Full Application may in turn be approved or denied subject Dermira, Inc.’s sole and absolute discretion. Dermira Inc.’s financial and/or product support is contingent upon full execution by both parties of a written Dermira Grant Agreement.

To inquire directly about current areas of interest and for any other questions, please contact us at